Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

March 24, 2016

Study Completion Date

March 24, 2016

Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
DRUG

SHP465 12.5mg capsules (one capsule daily)

one capsule daily

OTHER

Placebo

Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)

DRUG

SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)

One capsule daily

Trial Locations (45)

10016

Nyu Langone Medical Center, New York

10549

Bioscience Research Llc, Mount Kisco

20170

Neuroscience, Inc, Herndon

27609

Richard H Weisler, Md, Pa & Associates, Raleigh

29464

Coastal Carolina Research, Mt. Pleasant

29812

Rainbow Research, Inc., Barnwell

30060

Northwest Behavioral Research Center, Marietta

32256

Clinical Neuroscience Solutions, Inc, Jacksonville

32401

Florida Clinical Research Center Llc, Bradenton

32607

Sarkis Clinical Trials, Gainesville

32751

Florida Clinical Research Center, Llc, Maitland

32763

Medical Research Group of Central Florida, Orange City

32801

Clinical Neuroscience Solutions, Inc, Orlando

33143

Qps Mra, Llc, Miami

33912

Gulfcoast Clinical Research Center, Fort Myers

38119

Clinical Neuroscience Solutions, Memphis

45417

Midwest Clinical Research Center, Dayton

48307

Rochester Center For Behavioral Medicine, Rochester Hills

48314

Clinical Neurophysiology Services, Sterling Heights

60048

Capstone Clinical, Libertyville

60563

Baber Research Group, Inc, Naperville

63304

Midwest Research Group, Saint Charles

63368

Psychiatric Care and Research Center, O'Fallon

66211

Psychiatric Associates, Overland Park

68526

Premier Psychiatric Research Institutute, Lincoln

70114

Louisiana Research Associates, Inc., New Orleans

73103

Ips Research Company, Oklahoma City

75093

Research Across America, Plano

75231

Futuresearch Trials of Dallas, Lp, Dallas

77007

Bayou City Research, Ltd, Houston

77090

Red Oak Psychiatry Associates, Houston

77098

Houston Clinical Trials, Llc, Houston

80910

McB Clinical Research, Colorado Springs

89128

Center For Psychiatry and Behavioral Medicine, Inc, Las Vegas

90720

Pharmacology Research Institute (Pri), Los Alamitos

91316

Pharmacology Research Institute, Encino

92595

Elite Clinical Trials, Wildomar

92660

Pharmacology Research Institute (Pri), Newport Beach

92868

Nrc Research Institute, Orange

97214

Oregon Center For Clinical Investigations, Inc, Portland

97301

Oregon Center For Clinical Investigations, Salem

98033

Eastside Therapeutic Resource, Kirkland

98104

Summit Research Network (Seattle) Llc, Seattle

08540

Princeton Medical Institute, Princeton

02886

Omega Medical Research, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT02604407 - Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter